| Bioactivity | TAT-cyclo-CLLFVY TFA is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. TAT-cyclo-CLLFVY TFA disrupts HIF-1α/HIF-1β protein-protein interaction with an IC50 of 1.3 μM[1]. |
| Invitro | TAT-cyclo-CLLFVY inhibits HIF-1 activity in a mammalian cell luciferase reporter assay[1]. Hypoxia (1% O2) results in a ~12-fold increase in the luciferase signal, which is inhibited in a dose-dependent manner by TAT-cyclo-CLLFVY (IC50 of 19±2 μM)[1]. To assess the cell-specificity of TAT-cyclo-CLLFVY, the experiment is repeated in MCF-7 breast cancer cells with similar results (TAT-cyclo-CLLFVY IC50 of 16±1 μM)[1]. |
| Name | TAT-cyclo-CLLFVY TFA |
| Shortening | CGRKKRRQRRRPPQ.cyclo(CLLFVY) (Disulfide bridge:Cys1-Cys1') |
| Formula | C113H189F3N42O26S2 |
| Molar Mass | 2673.10 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
TAT-cyclo-CLLFVY TFA
CAS: F: C113H189F3N42O26S2 W: 2673.10
TAT-cyclo-CLLFVY TFA is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.